Literature DB >> 25473915

Reply to IL-18 is not therapeutic for neovascular age-related macular degeneration.

Sarah L Doyle1, Peter Adamson2, Francisco J López3, Peter Humphries4, Matthew Campbell4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25473915     DOI： 10.1038/nm.3741

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  10 in total

1.  NLRP3 inflammasome blockade inhibits VEGF-A-induced age-related macular degeneration.

Authors:  Alexander G Marneros
Journal:  Cell Rep       Date:  2013-09-05       Impact factor: 9.423

2.  NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components.

Authors:  Sarah L Doyle; Matthew Campbell; Ema Ozaki; Robert G Salomon; Andres Mori; Paul F Kenna; Gwyneth Jane Farrar; Anna-Sophia Kiang; Marian M Humphries; Ed C Lavelle; Luke A J O'Neill; Joe G Hollyfield; Peter Humphries
Journal:  Nat Med       Date:  2012-05       Impact factor: 53.440

3.  IL-18 is not therapeutic for neovascular age-related macular degeneration.

Authors:  Yoshio Hirano; Tetsuhiro Yasuma; Takeshi Mizutani; Benjamin J Fowler; Valeria Tarallo; Reo Yasuma; Younghee Kim; Ana Bastos-Carvalho; Nagaraj Kerur; Bradley D Gelfand; Sasha Bogdanovich; Shikun He; Xiaohui Zhang; Miho Nozaki; Ryo Ijima; Hiroki Kaneko; Yuichiro Ogura; Hiroko Terasaki; Hiroshi Nagai; Isao Haro; Gabriel Núñez; Balamurali K Ambati; David R Hinton; Jayakrishna Ambati
Journal:  Nat Med       Date:  2014-12       Impact factor: 53.440

4.  Interleukin-18 regulates pathological intraocular neovascularization.

Authors:  Hong Qiao; Koh-Hei Sonoda; Yasuhiro Ikeda; Takeru Yoshimura; Kuniaki Hijioka; Young-Joon Jo; Yukio Sassa; Chikako Tsutsumi-Miyahara; Yasuaki Hata; Shizuo Akira; Tatsuro Ishibashi
Journal:  J Leukoc Biol       Date:  2007-01-18       Impact factor: 4.962

5.  An essential role of Th1 responses and interferon gamma in infection-mediated suppression of neoplastic growth.

Authors:  Erinn B Rankin; Duonan Yu; Jiu Jiang; Hao Shen; Edward J Pearce; Michael H Goldschmidt; David E Levy; Tatyana V Golovkina; Christopher A Hunter; Andrei Thomas-Tikhonenko
Journal:  Cancer Biol Ther       Date:  2003 Nov-Dec       Impact factor: 4.742

6.  Sequence- and target-independent angiogenesis suppression by siRNA via TLR3.

Authors:  Mark E Kleinman; Kiyoshi Yamada; Atsunobu Takeda; Vasu Chandrasekaran; Miho Nozaki; Judit Z Baffi; Romulo J C Albuquerque; Satoshi Yamasaki; Masahiro Itaya; Yuzhen Pan; Binoy Appukuttan; Daniel Gibbs; Zhenglin Yang; Katalin Karikó; Balamurali K Ambati; Traci A Wilgus; Luisa A DiPietro; Eiji Sakurai; Kang Zhang; Justine R Smith; Ethan W Taylor; Jayakrishna Ambati
Journal:  Nature       Date:  2008-03-26       Impact factor: 49.962

7.  Interleukin-18 has antipermeablity and antiangiogenic activities in the eye: reciprocal suppression with VEGF.

Authors:  Jikui Shen; David F Choy; Tsunehiko Yoshida; Takeshi Iwase; Gulnar Hafiz; Bing Xie; Sean F Hackett; Joseph R Arron; Peter A Campochiaro
Journal:  J Cell Physiol       Date:  2014-08       Impact factor: 6.384

8.  A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer.

Authors:  Michael J Robertson; John M Kirkwood; Theodore F Logan; Kevin M Koch; Steven Kathman; Lyndon C Kirby; William N Bell; Linda M Thurmond; Jill Weisenbach; Mohammed M Dar
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

9.  Preclinical safety of recombinant human interleukin-18.

Authors:  Danuta J Herzyk; Peter J Bugelski; Timothy K Hart; Patrick J Wier
Journal:  Toxicol Pathol       Date:  2003 Sep-Oct       Impact factor: 1.902

10.  IL-18 attenuates experimental choroidal neovascularization as a potential therapy for wet age-related macular degeneration.

Authors:  Sarah L Doyle; Ema Ozaki; Kiva Brennan; Marian M Humphries; Kelly Mulfaul; James Keaney; Paul F Kenna; Arvydas Maminishkis; Anna-Sophia Kiang; Sean P Saunders; Emily Hams; Ed C Lavelle; Clair Gardiner; Padraic G Fallon; Peter Adamson; Peter Humphries; Matthew Campbell
Journal:  Sci Transl Med       Date:  2014-04-02       Impact factor: 17.956
  10 in total
  6 in total

1.  Inflammasomes Induced by 7-Ketocholesterol and Other Stimuli in RPE and in Bone Marrow-Derived Cells Differ Markedly in Their Production of IL-1β and IL-18.

Authors:  Guangpu Shi; Siqi Chen; Wambui S Wandu; Osato Ogbeifun; Lindsey F Nugent; Arvydas Maminishkis; Samuel J H Hinshaw; Ignacio R Rodriguez; Igal Gery
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-02-12       Impact factor: 4.799

Review 2.  Friend or Foe? Resident Microglia vs Bone Marrow-Derived Microglia and Their Roles in the Retinal Degeneration.

Authors:  Ni Jin; Lixiong Gao; Xiaotang Fan; Haiwei Xu
Journal:  Mol Neurobiol       Date:  2016-06-18       Impact factor: 5.590

Review 3.  Inflammation and its role in age-related macular degeneration.

Authors:  Anu Kauppinen; Jussi J Paterno; Janusz Blasiak; Antero Salminen; Kai Kaarniranta
Journal:  Cell Mol Life Sci       Date:  2016-02-06       Impact factor: 9.261

Review 4.  THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET.

Authors:  David S Boyer; Ursula Schmidt-Erfurth; Menno van Lookeren Campagne; Erin C Henry; Christopher Brittain
Journal:  Retina       Date:  2017-05       Impact factor: 4.256

5.  Chronic, Systemic Interleukin-18 Does Not Promote Macular Degeneration or Choroidal Neovascularization.

Authors:  Scott W Canna; Guangpu Shi; Igal Gery; H Nida Sen
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-03-01       Impact factor: 4.799

Review 6.  NLRP3 Inflammasome and Pathobiology in AMD.

Authors:  Lucia Celkova; Sarah L Doyle; Matthew Campbell
Journal:  J Clin Med       Date:  2015-01-14       Impact factor: 4.241
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.